Clinical-stage biopharmaceutical company Anavex Life Sciences Corp. is working on an investigational oral treatment for Alzheimer’s disease called ANAVEX 2-73, with full PART A data and preliminary PART B data from its ongoing Phase 2a clinical trial to be presented during the Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 5 and…
In a new study entitled “Histone Deacetylase Inhibition via RGFP966 Releases the Brakes on Sensory Cortical Plasticity and the Specificity of Memory Formation” a team of researchers at Rutgers University discovered that the drug RGFP966 changes how audible memory is formed and that RGFP966-treated rats have stronger memories that…
Clinical-stage biopharmaceutical company, Axovant Sciences Ltd., recently announced it has screened the first batch of patients for MINDSET, an international Phase III clinical trial exploring RVT-101 as a candidate treatment for Alzheimer’s disease. The company also reported the US Food and Drug Administration’s decision to grant MINDSET a Special Protocol Assessment…
Researchers at University of Southern California at Los Angeles (USC) Viterbi School of Engineering and Wake Forest Baptist Medical Center in Winston-Salem, North Carolina have developed a brain prosthesis designed to help individuals suffering from memory loss associated with Alzheimer’s Disease (AD) and other forms of dementia form new…
As a disease that is best detected and treated early after onset, Alzheimer disease is characterized by a variety of aberrantly regulated proteins and molecules, which once identified can be used as biomarkers for disease and integrated into Alzheimer’s diagnostic tests. New research at the University of Illinois at Chicago by co-authors Dr.
A recent communication from the University of Texas at Arlington reported that computer scientists led by Professor Heng Huang won a $2 million grant funded by the National Institutes of Health to investigate the possibility of predicting whether a person is predisposed to develop Alzheimer’s disease by analyzing complex genomics data.
In a recent paper published in the Nature Reviews in Neurology journal, a team of US researchers discussed the current challenges, opportunities and emerging evaluation methods in preclinical Alzheimer disease treatments, describing a convergent initiative to improve Alzheimer disease prevention research coined as Collaboration…
In a recent study entitled “A Hot-Segment-Based Approach for the Design of Cross-Amyloid Interaction Surface Mimics as Inhibitors of Amyloid Self-Assembly” and published in Angewandte Chemie, a team of scientists…
Results from a recent study conducted by scientists at the Universidad Nacional Autónoma de México, Instituto Nacional de Pediatría, Centro Médico Cozumel Universities of Montana, Valle de México, Boise State and North Carolina, revealed that air pollution has a harmful effect on hippocampal metabolites as early neurodegeneration markers among young urbanites…
According to a new analysis conducted by Alzheimer’s Research UK one in three people born in 2015 will develop Alzheimer’s Disease (AD) during their lifetime. The results suggest an alarming crisis in national health as the population in the United Kingdom ages, and highlights the demand for global efforts to develop new successful…
Get regular updates to your inbox.